In their assessment, FDA scientists said that patients who received MDMA and talk therapy showed ‘rapid, clinically meaningful, durable improvements in their PTSD symptoms.’
Revised CANMAT guidelines outline patient assessment, selection of evidence-based treatments, prevention of recurrence and strategies for managing inadequate response.